iMedi.co.uk

Out of date information, search another

Amsidine 50mg/Ml Injection

Out of date information, search another

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Amsidine 50mg/ml Injection

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1ml contains 50mg of Amsacrine.

3 PHARMACEUTICAL FORM

Amsidine is formulated as two sterile liquids combined for administration via intravenous infusion to human beings.

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

Amsidine is indicated for the induction and maintenance of remission in acute leukaemia of adults. It is effective in patients refractory to the anthracycline antibiotics used singly or in combination with other chemotherapeutic agents, and in patients who were formerly treated with maximum cumulative doses of these antibiotics.

4.2 Posology and method of administration

Intravenous infusion.

Amsidine must be diluted in 500ml 5% Dextrose Injection BP and infused over 60 to 90 minutes. Phlebitis or pain at the injection site may occur at

doses greater than 70 mg/m2. (NOTE: DO NOT USE OTHER DILUENTS. AMSIDINE IS INCOMPATIBLE WITH SALINE). Care must be taken that no extravasation occurs which might produce severe irritation or necrosis. Caution in the handling and preparation of the solution should be exercised, and the use of polyethylene gloves is recommended. If the solution of Amsidine contacts the skin or mucosae, immediately wash thoroughly with soap and water.

Adults

Induction of remission phase

The usual dosage of Amsidine in the induction phase is 90 mg/m2 every day

for five consecutive days (total dose 450 mg/m2 per course of treatment). If bone marrow biopsy performed on day six displays over 50% cellularity and the blasts count is over 30%, the treatment may be extended for an additional three days, bringing the total dose per course of treatment to 720 mg/m2.

More than one course of treatment may be required to achieve induction. Depending on the effectiveness of the first course in producing myelosuppression, the subsequent courses are given at two-week (if not effective) to four-week (if effective) intervals. In cases where a hypocellular marrow has not been achieved after the first course of treatment, the daily dose

of Amsidine may be escalated to 120 mg/m2 per day for the subsequent courses, provided that this is not contra-indicated for reasons of non-myelosuppressive toxicity.

For patients with impaired liver function or impaired renal function, the dose of Amsidine should be decreased by 20-30% (to 60-75 mg/m2 per day).

Maintenance phase

The maintenance dose is about one third the induction dose, given either as a single IV infusion or divided in three daily doses; e.g. 150mg/m2 given once every 3-4 weeks or 50mg/m2 per day for three consecutive days, repeated every 3-4 weeks.

Each maintenance course should bring down the granulocyte count to 1,000-1,500/pl and the platelet count to 50,000-100,000/pl    If this is not

accomplished, the maintenance dose may be escalated by 20% every second course. The granulocyte and platelet counts should be allowed to recover between the courses to over 1,500/pl and 100,000/pl respectively; otherwise the subsequent course should be delayed.

Elderly

Elimination may be slower in this group. This should be considered when designing dose schedules for the elderly.

Children under 12 Years: Not recommended.

4.3 Contraindications

•    Hypersensitivity to amsacrine or acridine derivates;

•    Hypersensitivity to any of the other ingredients of the product;

•    Clear bone-marrow-suppression as a result of treatment with cytostatics or radiotherapy;

•    Lactation.

4.4 Special warnings and precautions for use

Amsacrine should only be used under strict control of a specialised oncologist, with preference in institutions with experience with this kind of therapies. Patients should be hospitalised during the induction phase of treatment for close observation and extensive laboratory monitoring.

With recommended dose schedules, leucopenia is usually transient, reaching its nadir at 10-13 days after treatment, with recovery usually following by the 17th to 25th day. White blood cell counts of 1000/pl or lower are to be expected during treatment with appropriate doses of Amsidine. Doses higher than recommended may produce more severe or more prolonged marrow suppression.

Bone Marrow Suppression

Amsacrine can cause severe bone-marrow-depression, thus frequent blood control is necessary. Infections and hemorrhages can be fatal. With an alreadyexisting bone □ marrow □ depression caused by drugs, amsacrine should beadministered cautiously and with extra controls. Also if a too strong decrease in white blood cells or blood platelets occurs, interruption of the amsacrine treatment or decrease of dosage can be necessary. Red blood cells and platelets should be available for transfusion as well as other facilities for the treatment of bone-marrow-depression.

Hyperuricemia

Amsacrine can induce hyperuricemia secondary to rapid lysis of neoplastic cells. Careful monitoring of blood uric acid levels is recommended, in particular with regard to possible consequences for renal function. Consideration may be given to reducing uric acid levels prophylactically, prior to or concurrent with amsacrine treatment.

Patients with Hepatic or Renal Impairment

Toxicity at recommended doses is enhanced by hepatic or renal impairment. Laboratory evaluation of hepatic and renal function is necessary prior to and during administration. A dose reduction might be considered.

Adverse reactions

The physician should be aware of allergic reactions (anaphylaxia, oedema and skin reactions), GI problems and epileptic insults (epileptic seizures related to the use of amsacrine, can be treated according to standard regimen. Local necrosis can occur with extravasation of amsacrine (see section 4.8). Injection site irritation can be prevented by diluting amsacrine in a greater volume 5 % glucose and infusion is spread over a larger period of time (minimal 1 hour).

Cardiac function

Careful monitoring of cardiac rhythm is recommended for detection of cardiotoxicity. Patients with hypokalemia are at increased risk of ventricular fibrillation, also concurrent use of diuretics, aminoglycosides or other nephrotoxic drugs and previous exposure to other anthracycline therapy.The risk of developing arrhythmias can be minimized by ensuring a normal serum potassium level immediately prior to and during amsacrine administration.

Hypokalemia should be corrected prior to amsacrine administration.

CNS function

In the case of an exceedingly large fall in white cell count and excessive depression of bone marrow, suspension of treatment or reduction of dosage may be necessary.

Laboratory Tests

Complete blood counts, liver and renal function tests, and electrolytes should be performed regularly. Electrolytes should be re-evaluated before each day's treatment.

Pharmaceutical Precautions

Caution in handling and preparation of the solution should be exercised, and the use of polyethylene gloves is recommended (see enclosure leaflet). If the solution of Amsidine contacts the skin or mucosae, immediately wash thoroughly with soap and water. Amsidine must be diluted in 500ml 5% Dextrose Injection BP and infused over 60 to 90 minutes (Note: do not use other diluents, Amsidine is incompatible with saline). The solution when diluted for infusion is stable for eight hours at room temperature. It should be protected from exposure to sunlight, and any unused solution should be discarded. (see enclosure leaflet). Glass syringes must be used as Amsidine in solution reacts with plastic syringes.

The labelling contains the following statements: avoid contact with the skin and keep out of the reach of children.

4.5 Interaction with other medicinal products and other forms of interaction

Vaccines:

Concomitant influenza or pneumococcal vaccination and immunosuppressive therapy have been associated with impaired immune response to the vaccine.

Other Protein-binding Drugs:

Amsacrine may be displaced from serum albumin, with consequential increase in free drug and toxicity if used with other highly protein binding drugs.

Other Cytotoxic Agents:

Adverse effects may be potentiated by use with other cytotoxic agents.

4.6 Fertility, pregnancy and lactation

Data on the usage of this compound during pregnancy in patients are not available to judge possible harmfulness. However based on its pharmacologic activity harmfulness of treatment during pregnancy is possible.

In animal studies teratogenicity and other reproductivity toxicity has been observed (see section 5.3). Based on animal studies and the mechanism of action of the substance, use during pregnancy is discouraged, especially during the first trimester.

In every individual case the advantages of treatment should be weighed against the risks to the foetus.

Contraception in males and females

Due to the mechanism of action of amsacrine and possible adverse effects on the foetus, females should use effective contraception for 3 months after treatments and males for 6 months after treatment.

Fertility

Reversible azospermia in humans has been described.

Lactation

As it is not clear whether amsacrine is excreted in the mother milk, lactation is contraindicated.

4.7 Effects on ability to drive and use machines

No data about this influence are known. In view of reported adverse effects profile patients are advised after administration of amsacrine to be cautious when driving or using machines.

4.8 Undesirable effects

The most common adverse reactions are nausea and/or vomiting, anemia, fever and infection. Pain or phlebitis on infusion has been reported.

All patients treated with a therapeutic dosage of amsacrine show bone marrow depression. Main complications are infections and hemorrhages. Minimal white blood cells occur on day 5-12, usually followed with complete recovery on day 25. The pattern of inhibition of blood platelets is similar to that of leucocytes. As with other antineoplastic agents there is a possibility that prolonged use may lead to a carcinogenic effect. This should be borne in mind when undertaking long-term treatment.

In the table below all adverse events are presented according to classification of organ system and frequency, very common (>1/10); common (> 1/100 to <1/10); uncommon (>1/1000 to <1/100); rare (>1/10.000 to <1/1000); not known (cannot be estimated from the available data).

Infections and Infestations

Common

Infection

Blood and Lymphatic System Disorders

Common

Thrombocytopenia, pancytopenia, hemorrhage

Rare

Anemia, granulocytopenia, leukopenia

Not known

Bone marrow failure

Immune system disorders

Rare

Hypersensitivity, anaphylactic reaction, oedema

Metabolism and Nutrition Disorders

Common

Hypokalemia

Rare

weight decreased, weight increased

Not known

hyperuricaemia

Psychiatric Disorders

Common

Affect lability

Rare

Lethargy, confusion

Nervous System Disorders

Common

Grand mal seizure1

Rare

Headache, hypoesthesia, dizziness, periferal neuropathy

Eye disorders

Rare

Visual disturbances

Cardiac disorders

Common

Cardiotoxicity, arrhythmia, congestive heart failure

Rare

Atrial fibrillation, sinus tachycardia, ventricular fibrillation , ventricular arrhythmias, cardiomyopathy, bradycardia, ECG abnormal, ejection fraction decreased

Not known

Cardiac arrest

Vascular Disorders

Very common

Hypotension

Common

Hemorrhage

Respiratory, Thoracic and Mediastinal Disorders

Common

Dyspnea

Gastrointestinal Disorders

Very common

Nausea, vomiting (mild to moderate), diarrhea, abdominal pain, stomatitis

Hepatobiliary Disorders

Common

Hepatitis, jaundice, hepatic insufficiency (see section 4.2)

Skin and Subcutaneous Tissue Disorders

Very common

Purpura

Common

Alopecia, urticaria and rash

Renal and Urinary Disorders

Common

Hematuria

Rare

Anuria, proteinuria, acute renal insufficiency

General Disorders and Administration site Conditions

Very common

Infusion site phlebitis

Common

Pyrexia,

Injection site irritation, necrosis, skin inflammation5

Investigation

Very common

Hepatic enzymes increased (see section 4.4).

Rare

Blood bilirubin increased, blood urea increased, blood alkaline phosphatase increased, blood creatinine increased

1    somet1 sometimes paired with hypokalemia

2    especially in paediatric patients, pretreated with antracyclines fatal or lifethreathening, usually in patients with hypokalemia

4    Mucosa of mouth and tractus digestivus are frequently effected ranging in severity from mild to life-threatening. Total oral mucosa can be affected; recovery takes several weeks.

5    related to the concentration of amsacrine infused (see section 4.4)

4.9 Overdose

No specific antidote is known in case of overdosage. Treatment should be symptomatic and supportive.

Hemorrhage and infection, resulting from bone marrow hypoplasia or aplasia, may require intensive supportive treatment with red cell, granulocyte or platelet transfusions and appropriate antibiotics.

Vigourous symptomatic treatment may be necessary for severe mucositis, vomiting or diarrhea.

5    PHARMACOLOGICAL PROPERTIES

5.1    Pharmacodynamic properties

Amsidine is a sterile antitumour chemotherapeutic agent for intravenous infusion. Although not completely clarified, the mode of action of amsacrine is related to its property of binding the DNA through intercalation and external (electrostatic) forces. Amsacrine inhibits the synthesis of DNA while the RNA may not be directly affected. An additional mode of action, involving modification of cell membrane function, has been suggested.

5.2 Pharmacokinetic properties

Amsidine is administered by intravenous infusion. Amsidine has a low lipid solubility, and a relatively high molecular weight, so that it is unlikely that it would cross the blood-brain barrier. Amsidine distributes well in the body, except to the brain and CSF, and is therefore inactive against cerebral tumours.

Studies have shown that the plasma concentration time profiles of Amsidine in man are best described using a three compartment open model. The terminal half-life was found to be prolonged in patients with severe hepatic dysfunction. Work in animals has shown that after biotransformation in the liver, the metabolites of Amsidine are finally excreted in the bile by an active transport mechanism. The majority of Amsidine is excreted in its metabolised form. Studies in man have shown that 20% of the administered drug (free and metabolised) was eliminated in the urine within the first 8 hours, and a total of about 42% within 72 hours in one patient with normal renal function.

5.3 Preclinical safety data

No additional data of relevance.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

N,N Dimethylacetamide L Lactic Acid Water for Injection

6.2 Incompatibilities

Amsidine is incompatible with saline. Dextrose 5% Injection BP must be used for dilution of Amsidine. Other diluents should not be used.

6.3 Shelf life

Active vial - 36 months Diluent vial - 36 months

6.4 Special precautions for storage

Store in a dry place at a temperature not exceeding 25°C and protect from light.

6.5 Nature and contents of container

Active vial - 2 ml clear neutral glass ampoule containing Amsacrine solution 1.5ml.

Diluent vial - 20 ml amber glass vial containing diluent 13.5ml.

Each pack contains 6 ampoules of active and 6 vials of diluent.

6.6 Special precautions for disposal

Caution in handling and preparation of the solution should be exercised, and the use of polyethylene gloves is recommended (see enclosure leaflet). If the solution of Amsidine contacts the skin or mucosae, immediately wash thoroughly with soap and water. Amsidine must be diluted in 500ml 5% Dextrose Injection BP and infused over 60 to 90 minutes (Note: do not use other diluents, Amsidine is incompatible with saline). The solution when diluted for infusion is stable for eight hours at room temperature. It should be protected from exposure to sunlight, and any unused solution should be discarded. (see enclosure leaflet). Glass syringes must be used as Amsidine in solution reacts with plastic syringes.

7 MARKETING AUTHORISATION HOLDER

NordMedica A/S J^gersborg Alle 164 DK-2820 Gentofte Denmark

8    MARKETING AUTHORISATION NUMBER(S)

PL 39656/0002

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

3 March 1998

10 DATE OF REVISION OF THE TEXT

22/03/2015